HSCI's own Betuvax has applied to the Russian Ministry of Health for permission to conduct clinical trials of its coronavirus vaccine. Preclinical studies of the drug showed its effectiveness. The vaccine differs significantly from those already registered and, according to the company, may be especially in demand for people with chronic and autoimmune diseases, for children and the elderly, as well as for repeated, so-called booster vaccinations.